Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Relations Between Cognitive Complaints and Cognitive Scores Goals in Cancer: Assessment of Metamemory

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02212132
Recruitment Status : Completed
First Posted : August 8, 2014
Last Update Posted : August 6, 2015
Sponsor:
Information provided by (Responsible Party):
Centre Francois Baclesse

Brief Summary:
This pilot study is, in this new and original approach in cancer pathology, measure and explain the correspondence between perceived cognitive impairment (cognitive complaint) by cancer patients and their cognitive scores goals with tasks metamemory while controlling the anxiety and depression and fatigue factors of patients.

Condition or disease Intervention/treatment
Metamemory Memory Complaints Performance Mnemonic Cancer Other: behavioral assessments

Detailed Description:

The relationship between performance from neuropsychological tests and subjective complaints of cancer patients treated with chemotherapy or adjuvant hormone therapy is not clear, many studies have reported no significant correlation between these two measures: the perception of patients' their cognitive deficits is generally increased relative to that which is measured by neuropsychological testing.

The reason for this lack of association found is probably multifactorial. 1) It can be explained in part by methodological limitations in some studies (lack of sensitivity tests, experimental design). 2) psycho-order factors and fatigue are also an explanatory variable in the sense that literature data often show that cognitive complaints are correlated with levels of anxiety and depression and fatigue. 3) Finally, metacognition, often assessed in neurodegenerative diseases or even in normal aging to better understand its impact on cognitive disorders, including memory impairment, and the complaint has never been explored in patients with cancer.

Metacognition is a complex but highly sensitive to measure and understand the patient's complaint and correspondence or disagree with the actual performance concept. Metacognition refers A) metacognitive knowledge, ie knowledge of an individual's own cognitive processes; This is a non-dependent activity during which, upstream of the performance of any task, implement an appropriate strategy, anticipate and plan cognitive steps that would be necessary for its success general knowledge; and B) metacognitive experiences, ie knowledge that is based on a cognitive activity in progress, which allows to monitor and control the task in order to maintain or otherwise modify the cognitive processes involved.

While metacognitive knowledge (A) are assessed by multiple choice questionnaires, metacognitive experiences (B) allow targeted and precise fine measures of correspondence between the prediction performance by the patient himself and his actual performance a mnemonic task (for JOL and FOK Judgment of Learning for Feeling Of Knowing). Studies exploring the effects of age on metamemory usually show a deficit of these metacognitive experiences in normal aging compared to young subjects.

Collected at the time of learning, JOL is a prediction of future performance for information that have just been learned. More specifically, when learning words, the subject must judge its ability to further free recall for each item (quantitative data). This prediction is then compared to the actual memory performance found in the free recall task. This comparison allows to judge the accuracy of the prediction and therefore the accuracy of metamemory judgment.

The FOK corresponds to a prediction of performance information that could not be provided in free recall recognition. In practice, when an item is not recovered in free recall, the subject must judge its ability to recognize the correct answer among distractor responses.

Metacognitive processes can refer to the field of memory (metamemory) or attention (métaattention), but for now metamemory was much valued neuropsychological tests and the testing and are most successful and many more.


Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Time Perspective: Prospective
Official Title: Relations Between Cognitive Complaints and Cognitive Scores Goals in Cancer: Assessment of Metamemory
Study Start Date : April 2013
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Patient
Neuropsychological evaluation, psychopathological assessment and fatigue
Other: behavioral assessments
Neuropsychological evaluation, psychopathological assessment and fatigue

Control group
Neuropsychological evaluation, psychopathological assessment and fatigue
Other: behavioral assessments
Neuropsychological evaluation, psychopathological assessment and fatigue




Primary Outcome Measures :
  1. Evaluation of metamemory through questionnaires [ Time Frame: At study entry ]
    Comparison with questionnaires completed by healthy subjects matched controls.


Secondary Outcome Measures :
  1. Influence of anxiety and depression and fatigue factors on metamemory. [ Time Frame: At study entry ]
    Search by questionnaires the influence of anxiety and depression and fatigue factors on metamemory.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient being treated for a solid tumor or hematological
Criteria

Inclusion Criteria:

  • Patient being treated for a solid or hematologic malignancy;
  • Patients under 65 years of age;
  • Patients Grade 3 'end primary school "minimum (scale Barbizet);
  • Primary cancer of the central nervous system or brain metastases Absence;
  • No major cognitive disorders;
  • Lack of previous neurological;
  • Lack of personality disorders and evolutionary psychiatric pathology.

Exclusion Criteria:

  • Patients with paraneoplastic syndrome;
  • Scalable psychiatric pathology;
  • Refusal to participate;
  • Patients unable to meet the cognitive tests;
  • Use of drugs;
  • Heavy drinking.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02212132


Locations
Layout table for location information
France
Centre François Baclesse
Caen, France, 14076
Sponsors and Collaborators
Centre Francois Baclesse
Investigators
Layout table for investigator information
Principal Investigator: Florence JOLY, PhD Centre François Baclesse

Layout table for additonal information
Responsible Party: Centre Francois Baclesse
ClinicalTrials.gov Identifier: NCT02212132     History of Changes
Other Study ID Numbers: METACAN
First Posted: August 8, 2014    Key Record Dates
Last Update Posted: August 6, 2015
Last Verified: August 2015
Keywords provided by Centre Francois Baclesse:
metamemory
memory complaints
performance mnemonic
cancer